Moreover, Dr. Boasman reported that the combination of a Jak inhibitor (ruxolitinib) and an anti-CD47 antibody increased the expression of calreticulin, signaling a much stronger prophagocytic message in cells derived from primary myelofibrosis patients (57). Here, CALR is linked to myelofibrosis.